1. Home
  2. HTO vs PGEN Comparison

HTO vs PGEN Comparison

Compare HTO & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HTO

H2O America Common Stock

HOLD

Current Price

$47.94

Market Cap

1.7B

Sector

Utilities

ML Signal

HOLD

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$3.60

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTO
PGEN
Founded
1985
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Water Supply
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.5B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HTO
PGEN
Price
$47.94
$3.60
Analyst Decision
Hold
Buy
Analyst Count
1
5
Target Price
$58.00
$7.67
AVG Volume (30 Days)
401.6K
4.4M
Earning Date
10-27-2025
11-13-2025
Dividend Yield
3.51%
N/A
EPS Growth
14.49
N/A
EPS
3.17
N/A
Revenue
$804,224,000.00
$6,309,000.00
Revenue This Year
$9.75
$342.78
Revenue Next Year
$8.19
$478.46
P/E Ratio
$15.09
N/A
Revenue Growth
11.39
59.20
52 Week Low
$43.75
$0.65
52 Week High
$57.17
$5.23

Technical Indicators

Market Signals
Indicator
HTO
PGEN
Relative Strength Index (RSI) 56.74 44.22
Support Level $43.75 $3.44
Resistance Level $48.42 $3.92
Average True Range (ATR) 1.15 0.30
MACD 0.34 -0.06
Stochastic Oscillator 90.04 11.54

Price Performance

Historical Comparison
HTO
PGEN

About HTO H2O America Common Stock

H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come.

About PGEN Precigen Inc.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Share on Social Networks: